Medical School · Year 2 · Microbiology · includes a quiz and discussion video

Lecture 3: Gram-Positive Cocci

Unit 2.8: Microbiology

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe Staphylococcus species and their clinical syndromes
2. Explain MRSA and antibiotic resistance mechanisms
3. Describe Streptococcus species and classification
4. Explain streptococcal diseases and post-infectious complications
5. Describe Enterococcus and its clinical significance
6. Explain laboratory identification of gram-positive cocci

Lecture Outline

I. Staphylococcus Overview

The staphylococci constitute one of the most clinically important groups of bacteria, causing infections ranging from minor skin conditions to life-threatening invasive diseases. These organisms are ubiquitous in the environment and on human skin, making them frequent causes of both community-acquired and healthcare-associated infections. Understanding the characteristics that distinguish pathogenic from commensal staphylococci, and the virulence factors that enable disease, is essential for proper diagnosis and management of staphylococcal infections.

Staphylococci are gram-positive cocci that characteristically appear in irregular grape-like clusters when examined microscopically, a morphology resulting from cell division in multiple planes. The name derives from the Greek "staphyle" meaning grape. All staphylococci produce catalase, an enzyme that converts hydrogen peroxide to water and oxygen, distinguishing them from streptococci which are catalase-negative. This simple test performed by adding hydrogen peroxide to colonies and observing for bubble formation is the first step in differentiating gram-positive cocci. Staphylococci are facultative anaerobes capable of both aerobic and anaerobic metabolism, and they demonstrate remarkable environmental resilience, tolerating high salt concentrations (growth in 7.5% sodium chloride), desiccation, and temperature extremes. This hardiness allows them to survive on skin, in the environment, and on fomites, facilitating transmission.

The staphylococci are divided into coagulase-positive and coagulase-negative species, a distinction with major clinical implications. Staphylococcus aureus is the sole coagulase-positive species of clinical significance and is by far the most pathogenic staphylococcal species. It produces coagulase, an enzyme that converts fibrinogen to fibrin, and also ferments mannitol, producing yellow colonies on mannitol salt agar. The coagulase-negative staphylococci (CoNS) include Staphylococcus epidermidis, the most common species on human skin that primarily causes device-associated infections through biofilm formation; Staphylococcus saprophyticus, a common cause of urinary tract infections in young sexually active women; and Staphylococcus lugdunensis, which despite being coagulase-negative behaves clinically more like S. aureus, causing aggressive infections including native valve endocarditis and skin abscesses.

Staphylococcus aureus possesses a formidable array of virulence factors that contribute to its pathogenicity. Protein A is a cell wall component that binds the Fc portion of immunoglobulin G in the wrong orientation, preventing opsonization and phagocytosis. Coagulase and clumping factor cause fibrin deposition around the bacteria, potentially protecting them from phagocytosis. Catalase destroys hydrogen peroxide produced by phagocytes during the oxidative burst. Multiple hemolysins (alpha, beta, gamma, and delta toxins) lyse red blood cells and other cell types. Panton-Valentine leukocidin (PVL) specifically destroys neutrophils and is associated with community-acquired MRSA strains and severe necrotizing infections. Enterotoxins cause staphylococcal food poisoning through direct action on the gastrointestinal tract and are heat-stable, remaining active even after cooking contaminated food. Toxic shock syndrome toxin-1 (TSST-1) is a superantigen causing toxic shock syndrome. Exfoliative toxins (exfoliatins) cleave desmoglein-1 in the epidermis, causing the skin sloughing of staphylococcal scalded skin syndrome. Additionally, S. aureus produces numerous enzymes including hyaluronidase for tissue spread, lipases enabling skin colonization, staphylokinase for dissolving clots, and beta-lactamases (penicillinases) that destroy penicillin antibiotics.

<image>Panel A: Microscopic appearance of Staphylococcus showing gram-positive cocci arranged in irregular grape-like clusters after Gram staining, with purple-stained spherical cells of approximately 1 micrometer diameter clustered together, contrasted with an inset showing the catalase test with bubbles forming when hydrogen peroxide is added to colonies. Panel B: Comparison chart of major Staphylococcus species showing S. aureus (coagulase-positive, gold colonies on blood agar, mannitol fermenter), S. epidermidis (coagulase-negative, white colonies, biofilm-forming, novobiocin-sensitive), S. saprophyticus (coagulase-negative, novobiocin-resistant, causes UTI), and S. lugdunensis (coagulase-negative, aggressive like S. aureus), with key distinguishing features for each. Panel C: Diagram of S. aureus virulence factors showing the bacterial cell with labeled components: protein A binding IgG Fc region incorrectly, capsule providing antiphagocytic protection, coagulase converting fibrinogen to fibrin, and secreted factors including alpha-toxin pores, PVL attacking neutrophils, and various enzymes (hyaluronidase, lipase, beta-lactamase) with their functions indicated. Panel D: Major S. aureus toxins illustrated with their clinical effects: enterotoxins causing food poisoning with rapid-onset vomiting, TSST-1 superantigen causing toxic shock syndrome with fever and rash, and exfoliative toxins cleaving desmoglein-1 causing epidermal separation in scalded skin syndrome, each with a small clinical image representation.</image>

II. Staphylococcus aureus Infections

Staphylococcus aureus causes a remarkably diverse spectrum of human disease, reflecting its extensive virulence factor repertoire and ability to colonize and infect virtually any tissue. Clinical syndromes range from localized skin infections that may resolve spontaneously to rapidly fatal invasive diseases requiring intensive medical intervention. The organism can cause disease through direct tissue invasion and inflammation, through toxin-mediated effects without significant local infection, or through combinations of both mechanisms.

Skin and soft tissue infections represent the most common clinical manifestations of S. aureus disease. Impetigo is a superficial skin infection producing characteristic honey-crusted lesions, common in children and highly contagious. Folliculitis involves infection of hair follicles, presenting as pustules at follicular orifices. When folliculitis extends deeper to involve the entire follicle and surrounding tissue, a furuncle (boil) develops, appearing as a painful, erythematous nodule that may spontaneously drain purulent material. A carbuncle represents confluent infection of multiple adjacent furuncles, forming a larger inflammatory mass often with multiple drainage points, typically occurring on the posterior neck. Cellulitis is a spreading infection of the dermis and subcutaneous tissue characterized by erythema, warmth, and swelling without clear demarcation, while abscesses are localized collections of pus walled off by inflammatory tissue. S. aureus skin infections frequently begin from minor trauma, insect bites, or colonized sites like the nares, and in the era of community-acquired MRSA, have become increasingly common and difficult to treat.

Invasive S. aureus infections carry significant morbidity and mortality. Bacteremia may arise from skin infections, intravascular catheters, or without identifiable source, and carries risk of seeding distant sites. Infective endocarditis caused by S. aureus is typically acute and destructive, affecting either the tricuspid valve in intravenous drug users or the mitral and aortic valves in others, with high rates of complications including heart failure, embolic events, and death. Osteomyelitis may develop from hematogenous seeding (especially in children) or from contiguous spread from overlying soft tissue infection or trauma. Septic arthritis usually involves a single large joint, most commonly the knee, presenting with acute pain, swelling, and limited range of motion. Pneumonia caused by S. aureus is severe and often occurs following influenza infection, which damages respiratory epithelium and predisposes to bacterial superinfection, or as a healthcare-associated infection in ventilated patients. S. aureus pneumonia frequently causes necrotizing infection with abscess formation and empyema.

Toxin-mediated diseases caused by S. aureus produce characteristic syndromes even when the bacterial burden is minimal. Staphylococcal food poisoning results from ingestion of preformed enterotoxins in contaminated food, with onset of nausea, vomiting, and diarrhea within one to six hours of consumption. Because the toxin is heat-stable, it remains active even after cooking kills the bacteria. Recovery is typically rapid within 24 hours. Toxic shock syndrome (TSS) is caused by TSST-1 or certain enterotoxins acting as superantigens, classically associated with tampon use but also occurring with wound infections and nasal packing. TSS presents with high fever, diffuse erythematous rash (sunburn-like), hypotension, and multiorgan dysfunction; desquamation of palms and soles occurs during recovery. Staphylococcal scalded skin syndrome (SSSS) predominantly affects infants and young children, caused by exfoliative toxins that circulate systemically and cleave desmoglein-1 in the superficial epidermis. The resulting separation produces widespread erythema and fragile bullae that rupture easily, leaving denuded areas resembling scalding burns.

<image>Panel A: Progression of S. aureus skin and soft tissue infections illustrated from superficial to deep: impetigo showing honey-crusted lesions on a child's face, folliculitis as small pustules at hair follicles, furuncle as a deep erythematous nodule with central pustule, carbuncle as a larger multi-headed lesion on the posterior neck, and cross-sectional diagram showing depth of involvement for each type. Panel B: S. aureus invasive infections depicted: endocarditis showing vegetations on a heart valve with septic emboli traveling to brain and kidney, osteomyelitis in a long bone with area of bone destruction and sequestrum formation, septic arthritis with swollen joint containing purulent fluid, and severe necrotizing pneumonia with abscess cavities on chest X-ray. Panel C: Toxic shock syndrome pathophysiology and presentation showing TSST-1 superantigen cross-linking MHC class II to TCR causing massive T cell activation and cytokine release, leading to clinical features: high fever, diffuse sunburn-like rash, hypotension, multiorgan involvement, and desquamation of palms and soles during recovery, with timeline of disease course. Panel D: Staphylococcal scalded skin syndrome mechanism and appearance showing exfoliative toxin circulation from localized infection site to skin, cleavage of desmoglein-1 in the granular layer causing epidermal splitting, clinical appearance with widespread erythema, flaccid bullae, and positive Nikolsky sign, with comparison to Stevens-Johnson syndrome which involves full-thickness epidermal necrosis.</image>

III. Coagulase-Negative Staphylococci

The coagulase-negative staphylococci (CoNS) were long considered non-pathogenic contaminants, but their clinical importance has grown dramatically with the increasing use of indwelling medical devices and the expansion of immunocompromised patient populations. While individually less virulent than S. aureus, CoNS cause substantial morbidity through their ability to form biofilms on foreign materials and their intrinsic resistance to many antibiotics. Distinguishing true CoNS infection from contamination remains a common clinical challenge.

Staphylococcus epidermidis is the most abundant organism on human skin and the most common CoNS causing clinical infections. Its primary virulence mechanism is formation of biofilm on prosthetic materials, including intravascular catheters, prosthetic heart valves, orthopedic implants, and cerebrospinal fluid shunts. Biofilm formation begins with adhesion to the device surface, followed by accumulation of bacteria within a self-produced extracellular matrix of polysaccharides and proteins. Bacteria within biofilms are protected from antibiotics and host immune responses, making these infections extremely difficult to eradicate without device removal. Prosthetic valve endocarditis caused by S. epidermidis typically presents indolently months to years after valve placement, in contrast to the acute presentation of S. aureus endocarditis. Catheter-related bloodstream infections are common in hospitalized patients and may require catheter removal for cure. Treatment typically requires vancomycin due to high rates of methicillin resistance among S. epidermidis, and surgical intervention for device removal is frequently necessary.

Staphylococcus saprophyticus is the second most common cause of urinary tract infections in young, sexually active women after Escherichia coli. Unlike most CoNS, S. saprophyticus has specific tropism for the urinary tract, possessing adhesins and urease that facilitate colonization of urinary epithelium. Patients present with typical cystitis symptoms including dysuria, frequency, and suprapubic discomfort. In the laboratory, S. saprophyticus is distinguished from S. epidermidis by resistance to novobiocin. Treatment with trimethoprim-sulfamethoxazole or fluoroquinolones is typically effective. Staphylococcus lugdunensis, though coagulase-negative, behaves clinically much like S. aureus and should be regarded with similar concern. It causes aggressive infections including native valve endocarditis, skin abscesses, and bone and joint infections. Unlike most CoNS, S. lugdunensis often remains susceptible to beta-lactam antibiotics, so accurate identification is important for appropriate therapy.

A persistent challenge with CoNS is determining whether their presence in clinical specimens represents true infection or contamination. Because these organisms are abundant on skin, they frequently contaminate blood cultures during venipuncture. A single blood culture positive for CoNS is more likely to represent contamination than true bacteremia, whereas multiple positive cultures from separate draws suggest true infection. Clinical context is crucial: CoNS isolated from blood in a patient with a central venous catheter, prosthetic heart valve, or other indwelling device are much more likely to be clinically significant. Signs of systemic infection including fever, elevated inflammatory markers, and clinical deterioration support true infection. In ambiguous cases, obtaining additional cultures before initiating treatment can help clarify the clinical picture.

<image>Panel A: S. epidermidis biofilm formation on a central venous catheter shown in sequential stages: initial adhesion of planktonic bacteria to the catheter surface, accumulation and microcolony formation, maturation with extracellular matrix production and three-dimensional structure, and detachment of bacteria that may disseminate, with electron microscopy-style images of each stage and labels indicating the polysaccharide intercellular adhesin (PIA) matrix. Panel B: S. epidermidis clinical infections depicted: prosthetic valve endocarditis showing biofilm on a mechanical valve with vegetation, infected orthopedic hardware with surrounding tissue inflammation, cerebrospinal fluid shunt infection with meningitis, and central line-associated bloodstream infection with inflamed catheter exit site. Panel C: S. saprophyticus urinary tract infection illustrated showing the organism's route of infection ascending the urethra to the bladder, adhesion to uroepithelium via specific adhesins, urease activity producing ammonia and alkalinizing urine, clinical presentation with dysuria and frequency in a young woman, and laboratory identification showing novobiocin resistance distinguishing it from S. epidermidis. Panel D: Decision algorithm for evaluating positive CoNS blood cultures showing branching logic: single positive culture (likely contamination, repeat cultures) versus multiple positive cultures (consider true infection); presence of risk factors (indwelling device, prosthetic valve, immunocompromise) increasing likelihood of true infection; and clinical signs (fever, elevated WBC, CRP) supporting true infection, with recommended actions at each decision point.</image>

IV. Streptococcus Overview

The streptococci are a diverse group of gram-positive cocci that include several of the most important human pathogens. Like staphylococci, they are ubiquitous in the environment and comprise part of the normal human flora, yet certain species cause severe invasive diseases and serious post-infectious complications. The classification of streptococci has evolved over time and incorporates multiple systems based on hemolysis patterns, cell wall carbohydrate antigens, and molecular characteristics. Understanding these classification schemes is essential for accurate identification and clinical decision-making.

Streptococci appear as gram-positive cocci arranged in chains or pairs, reflecting their pattern of cell division in a single plane. Unlike staphylococci, streptococci are catalase-negative, the key test distinguishing these two major groups of gram-positive cocci. Most streptococci are facultative anaerobes, though some are obligate anaerobes. They vary in their growth requirements, with some species growing readily on standard media while others require enriched media or specific atmospheric conditions. Streptococci do not form spores and are generally less environmentally resilient than staphylococci.

The hemolysis pattern on blood agar plates provides the primary basis for streptococcal classification and is the first observation made in the laboratory when working with these organisms. Alpha-hemolysis produces a greenish discoloration around colonies due to partial reduction of hemoglobin to methemoglobin; important alpha-hemolytic species include Streptococcus pneumoniae and the viridans group streptococci. Beta-hemolysis produces a clear zone of complete red blood cell lysis around colonies; beta-hemolytic streptococci include Streptococcus pyogenes (Group A) and Streptococcus agalactiae (Group B), both major human pathogens. Gamma-hemolysis, also called non-hemolytic, produces no change in the surrounding agar; the enterococci were formerly classified as gamma-hemolytic streptococci but are now recognized as a separate genus.

The Lancefield classification system, developed by Rebecca Lancefield in the 1930s, categorizes beta-hemolytic streptococci based on carbohydrate antigens in the cell wall. Group A streptococci (Streptococcus pyogenes) are among the most important human pathogens, causing pharyngitis, skin infections, invasive disease, and triggering post-infectious sequelae. Group B streptococci (Streptococcus agalactiae) colonize the genital and gastrointestinal tracts and are the leading cause of neonatal sepsis and meningitis. Groups C and G streptococci, particularly Streptococcus dysgalactiae subspecies equisimilis, cause infections similar to but generally less severe than Group A streptococci. The former Group D streptococci have been reclassified, with enterococci becoming a separate genus and Streptococcus bovis group organisms remaining in Streptococcus. For practical purposes, streptococci are often considered in three clinical categories: beta-hemolytic streptococci identified by Lancefield grouping, Streptococcus pneumoniae (alpha-hemolytic, distinguished by optochin sensitivity and bile solubility), and viridans group streptococci (alpha-hemolytic, optochin-resistant).

<image>Panel A: Microscopic appearance of streptococci showing gram-positive cocci in chains of varying lengths after Gram staining, with an inset showing the negative catalase test (no bubbles when hydrogen peroxide is added), contrasting with the positive catalase test of staphylococci. Panel B: Hemolysis patterns on blood agar plates displayed side by side: alpha-hemolysis showing greenish discoloration around colonies (S. pneumoniae, viridans strep), beta-hemolysis showing clear zones of complete lysis around colonies (S. pyogenes, S. agalactiae), and gamma-hemolysis showing no change in the agar (Enterococcus), with labeled arrows pointing to the characteristic zones. Panel C: Lancefield classification system diagram showing the major groups: Group A (S. pyogenes) with diseases listed, Group B (S. agalactiae) with neonatal focus, Groups C and G (S. dysgalactiae), and former Group D divided into Enterococcus (now separate genus) and S. bovis/gallolyticus group, with representative cell wall carbohydrate antigens depicted schematically. Panel D: Clinical streptococcal classification scheme showing the three major categories: beta-hemolytic streptococci (identified by Lancefield grouping, major pathogens causing acute infections), S. pneumoniae (alpha-hemolytic, optochin-sensitive, pneumonia/meningitis/otitis), and viridans group streptococci (alpha-hemolytic, optochin-resistant, normal oral flora, endocarditis), with key identifying features and common diseases for each.</image>

V. Streptococcus pyogenes (Group A Strep)

Streptococcus pyogenes, also known as Group A Streptococcus (GAS), ranks among the most significant human pathogens, causing an estimated 700 million infections annually worldwide and responsible for over 500,000 deaths. This organism produces an impressive array of virulence factors that enable it to cause diverse clinical syndromes, from self-limited pharyngitis to rapidly fatal necrotizing fasciitis. Additionally, GAS infections can trigger serious post-infectious autoimmune conditions that may cause permanent damage to the heart, kidneys, and other organs. Despite its pathogenic prowess, S. pyogenes has remained universally susceptible to penicillin, making treatment straightforward once the diagnosis is established.

The virulence factors of S. pyogenes contribute to adherence, invasion, immune evasion, and tissue damage. The M protein is the most important virulence factor, an antiphagocytic surface protein that inhibits complement deposition and serves as the basis for strain typing (over 200 M types exist). The hyaluronic acid capsule provides additional protection from phagocytosis and is chemically identical to human hyaluronic acid, reducing immunogenicity. Streptolysin O is an oxygen-labile hemolysin that forms pores in cell membranes and is highly immunogenic; the anti-streptolysin O (ASO) antibody titer is used clinically as evidence of recent GAS infection. Streptolysin S is an oxygen-stable hemolysin responsible for the beta-hemolysis observed on blood agar and is not immunogenic. Streptococcal pyrogenic exotoxins (Spe proteins, including SpeA, SpeB, and SpeC) function as superantigens, causing massive non-specific T cell activation and cytokine release, and are responsible for the rash of scarlet fever and the pathophysiology of streptococcal toxic shock syndrome. Additional enzymes including streptokinase (dissolves fibrin clots), hyaluronidase (degrades connective tissue), and streptodornase (degrades DNA) facilitate bacterial spread through tissues.

Suppurative infections caused by S. pyogenes span a spectrum of severity. Pharyngitis is the most common GAS infection, presenting with sore throat, fever, tonsillar exudates, and tender anterior cervical lymphadenopathy. Diagnosis by rapid antigen detection test or throat culture is important because antibiotic treatment prevents rheumatic fever, speeds symptom resolution, and reduces transmission. Scarlet fever occurs when pharyngitis is accompanied by a diffuse erythematous rash with a sandpaper texture, caused by pyrogenic exotoxins. Impetigo is a superficial skin infection producing honey-crusted lesions, more commonly caused by GAS than S. aureus in many regions. Cellulitis and erysipelas are skin infections involving deeper tissue; erysipelas is distinguished by sharply demarcated, raised borders and was historically called St. Anthony's fire. Necrotizing fasciitis is the most severe GAS soft tissue infection, a rapidly progressive infection of the fascia and overlying tissue that can destroy tissue faster than it can be surgically debrided, with mortality rates of 20 to 40 percent even with optimal treatment. Risk factors include minor trauma, recent varicella infection, and immunocompromise, though cases occur in previously healthy individuals.

Diagnosis of GAS infection depends on the clinical syndrome. For pharyngitis, rapid antigen detection tests offer point-of-care results with high specificity but moderate sensitivity; negative rapid tests in children should be confirmed by throat culture. Culture on blood agar demonstrating beta-hemolysis followed by Lancefield grouping or detection of pyrrolidonyl arylamidase (PYR) activity confirms identification. For post-infectious sequelae, serologic tests including ASO and anti-DNase B titers demonstrate evidence of recent infection. Treatment of GAS infection is straightforward: penicillin remains the drug of choice, and no penicillin-resistant strains have ever been documented. This remarkable susceptibility may relate to the essentiality of penicillin-binding proteins for GAS survival or to fitness costs of resistance. For patients with penicillin allergy, alternatives include first-generation cephalosporins (if not anaphylactic allergy), macrolides, or clindamycin. For invasive infections, clindamycin is often added to penicillin because it inhibits toxin production and remains active regardless of bacterial growth phase.

<image>Panel A: S. pyogenes virulence factors illustrated on a bacterial cell diagram: M protein projecting from the surface inhibiting complement C3b deposition and phagocytosis, hyaluronic acid capsule surrounding the cell resembling host tissue, streptolysin O creating pores in a nearby cell membrane, streptolysin S associated with the cell surface, and secreted enzymes (streptokinase, hyaluronidase, streptodornase) with their substrates and functions indicated by arrows. Panel B: GAS pharyngitis and scarlet fever presentation showing a throat with tonsillar erythema and exudates, tender anterior cervical lymph nodes palpated on examination, scarlet fever rash with sandpaper texture, strawberry tongue (early white-coated then red with prominent papillae), and Pastia lines (linear intensification in skin folds), with diagnostic algorithm showing rapid antigen test and culture pathway. Panel C: Spectrum of GAS skin and soft tissue infections progressing from superficial to deep: impetigo with honey-crusted lesions, erysipelas with sharply demarcated raised erythematous borders, cellulitis with diffuse spreading erythema and edema, and necrotizing fasciitis showing dusky discoloration, bullae, and crepitus, with cross-sectional diagram showing depth of tissue involvement for each. Panel D: Necrotizing fasciitis progression and treatment showing early subtle findings (pain out of proportion, dusky discoloration), rapid advancement over hours with tissue necrosis, surgical appearance during debridement showing gray necrotic fascia with dishwater purulent fluid, and treatment approach with emergent surgical debridement plus combination antibiotic therapy (penicillin plus clindamycin), with mortality statistics displayed.</image>

VI. Post-Streptococcal Diseases

Following certain Streptococcus pyogenes infections, autoimmune complications may develop that cause damage to distant organs weeks after the initial infection has resolved. These post-streptococcal diseases result from aberrant immune responses triggered by molecular mimicry between streptococcal antigens and host tissues, or from immune complex deposition. Recognizing and preventing these complications is a major goal of treating GAS infections, particularly pharyngitis. The two principal post-streptococcal syndromes are acute rheumatic fever and post-streptococcal glomerulonephritis, which differ in their triggering infections, mechanisms, and responsiveness to antibiotic prevention.

Acute rheumatic fever (ARF) is an inflammatory condition affecting the heart, joints, brain, and skin that develops two to four weeks after GAS pharyngitis. The pathogenesis involves molecular mimicry: antibodies generated against streptococcal antigens, particularly M protein, cross-react with host tissues including cardiac myosin and valve tissue. This autoimmune attack causes inflammation that, with recurrent episodes, leads to permanent scarring and deformity of heart valves, producing rheumatic heart disease. The diagnosis of ARF requires evidence of preceding GAS infection (positive culture, rapid test, or elevated ASO/anti-DNase B titers) plus clinical criteria. The Jones criteria specify major manifestations (carditis, migratory polyarthritis, Sydenham chorea, erythema marginatum, and subcutaneous nodules) and minor manifestations (fever, arthralgia, elevated inflammatory markers, prolonged PR interval). Initial episodes require two major criteria, or one major plus two minor criteria, along with evidence of prior GAS infection. Carditis, occurring in 50 to 70 percent of initial episodes, is the most serious manifestation, causing pancarditis with particular involvement of the mitral valve (and aortic valve to a lesser extent). Chronic rheumatic heart disease remains a major cause of cardiovascular morbidity and mortality in developing countries.

Post-streptococcal glomerulonephritis (PSGN) develops one to three weeks after GAS pharyngitis or skin infection, distinguishing it from ARF which follows only pharyngitis. The mechanism involves deposition of immune complexes (streptococcal antigen-antibody complexes) in glomerular capillaries, activating complement and triggering inflammation. Patients present with the nephritic syndrome: hematuria (often with red blood cell casts), proteinuria, edema, and hypertension. Serum complement levels, particularly C3, are characteristically decreased due to consumption. Unlike ARF, PSGN is not prevented by antibiotic treatment of the preceding infection, as immune complex formation has already occurred by the time symptoms appear. The prognosis is generally excellent in children, with most recovering renal function completely, though adults may have more persistent abnormalities. PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections) is a controversial entity in which obsessive-compulsive symptoms and tics develop following GAS infection, hypothesized to result from autoimmune attack on basal ganglia, but the association and mechanism remain debated.

The critical distinction between ARF and PSGN lies in preventability. Antibiotic treatment of GAS pharyngitis prevents ARF by eliminating the antigenic stimulus before the autoimmune response develops; this is the primary rationale for treating strep throat. However, antibiotics do not prevent PSGN because immune complex formation has already occurred by the time skin or pharyngeal infection is recognized. Recurrent GAS pharyngitis poses particular risk for rheumatic fever recurrence, which tends to involve the same organ systems as the initial episode, progressively worsening valvular damage. Secondary prophylaxis with regular penicillin (monthly intramuscular injections or daily oral dosing) prevents recurrent pharyngitis and is recommended for patients with documented ARF, with duration depending on the presence and severity of carditis.

<image>Panel A: Acute rheumatic fever pathogenesis and manifestations showing the timeline from GAS pharyngitis (week 0) to ARF onset (weeks 2-4), molecular mimicry between streptococcal M protein and cardiac myosin causing autoantibody production, and the Jones criteria major manifestations: carditis with pancarditis affecting mitral valve predominantly, migratory polyarthritis moving between large joints, Sydenham chorea with involuntary movements, erythema marginatum as annular rash on trunk, and subcutaneous nodules over bony prominences. Panel B: Rheumatic heart disease progression showing initial episode causing valve inflammation, recurrent episodes causing progressive scarring and deformity, final stage with stenotic mitral valve (fish-mouth appearance), clinical findings of mitral stenosis murmur, and global distribution map highlighting disease burden in developing countries. Panel C: Post-streptococcal glomerulonephritis mechanism and presentation showing immune complex (streptococcal antigen-antibody) deposition in glomerular capillaries, complement activation and inflammatory infiltrate, electron microscopy appearance with subepithelial humps, and clinical presentation with cola-colored urine (hematuria), periorbital edema, hypertension, and laboratory findings (low C3, red cell casts on urinalysis). Panel D: Comparison of ARF and PSGN in a side-by-side format: triggering infection (pharyngitis only versus pharyngitis or skin), mechanism (molecular mimicry versus immune complexes), timing (2-4 weeks versus 1-3 weeks), prevention by antibiotics (yes for ARF, no for PSGN), recurrence risk (high for ARF, low for PSGN), and long-term complications (rheumatic heart disease versus usually complete recovery).</image>

VII. Other Streptococci

Beyond Streptococcus pyogenes, several other streptococcal species cause important human diseases. Group B Streptococcus is the leading cause of life-threatening neonatal infections, Streptococcus pneumoniae remains a major cause of pneumonia, meningitis, and otitis media despite effective vaccines, and the viridans group streptococci are the classic cause of subacute bacterial endocarditis. Understanding the epidemiology, clinical presentations, and prevention strategies for each of these organisms is essential for clinical practice.

Streptococcus agalactiae, Group B Streptococcus (GBS), colonizes the vaginal and gastrointestinal tracts of approximately 25 percent of healthy women. During vaginal delivery, infants may acquire the organism and develop serious invasive disease including sepsis, pneumonia, and meningitis. Early-onset GBS disease occurs within the first week of life, typically within 24 hours of birth, and manifests as sepsis and pneumonia acquired during passage through the birth canal. Late-onset disease occurs from one week to three months of age and more commonly presents as meningitis, likely acquired from maternal, nosocomial, or community sources. Risk factors for neonatal GBS disease include prolonged rupture of membranes, prematurity, maternal GBS bacteriuria, and previous infant with GBS disease. Prevention relies on universal screening of pregnant women at 35 to 37 weeks gestation with vaginal-rectal culture and administration of intrapartum antibiotic prophylaxis (typically penicillin or ampicillin) to colonized women during labor. This strategy has dramatically reduced early-onset GBS disease. In adults, GBS causes invasive infections primarily in elderly individuals and those with diabetes, malignancy, or other immunocompromising conditions, including bacteremia, pneumonia, skin and soft tissue infections, and bone and joint infections.

Streptococcus pneumoniae (the pneumococcus) is a lancet-shaped gram-positive diplococcus that is alpha-hemolytic and distinguished from other alpha-hemolytic streptococci by sensitivity to optochin and solubility in bile. Its polysaccharide capsule is the major virulence factor, with over 90 serotypes identified based on capsular antigens. The capsule inhibits phagocytosis, and anticapsular antibodies are protective, forming the basis for pneumococcal vaccines. S. pneumoniae causes community-acquired pneumonia (the most common bacterial cause), bacterial meningitis (the most common cause in adults), acute otitis media, and sinusitis. Invasive disease is most common in young children, elderly adults, and immunocompromised individuals, including those with asplenia, HIV infection, or hypogammaglobulinemia. Penicillin resistance has emerged and increased over recent decades, mediated by alterations in penicillin-binding proteins acquired through transformation from related streptococcal species. Resistance rates vary geographically and affect treatment decisions for meningitis and other serious infections. Pneumococcal vaccines include the 13-valent conjugate vaccine (PCV13) recommended for young children and certain adults, and the 23-valent polysaccharide vaccine (PPSV23) recommended for adults over 65 and those with risk factors.

The viridans group streptococci are a heterogeneous collection of alpha-hemolytic (or non-hemolytic) species that are optochin-resistant, distinguishing them from S. pneumoniae. They comprise the predominant flora of the oral cavity and include Streptococcus mutans (the primary cause of dental caries), Streptococcus mitis, Streptococcus sanguinis, and others. Their major clinical significance is as causes of subacute bacterial endocarditis (SBE), an indolent infection of heart valves that typically affects previously abnormal valves. Transient bacteremia following dental procedures allows oral streptococci to seed damaged or abnormal valves, where they establish infection. Patients present with weeks to months of low-grade fever, malaise, and constitutional symptoms, often with embolic phenomena. Streptococcus gallolyticus (formerly Streptococcus bovis) is associated with colorectal cancer, and its isolation from blood cultures warrants colonoscopy to evaluate for occult malignancy.

<image>Panel A: Group B Streptococcus neonatal disease prevention strategy showing pregnant woman undergoing vaginal-rectal swab at 35-37 weeks, culture incubation and identification, positive result prompting intrapartum IV penicillin during labor, and protected neonate; alongside timeline showing early-onset disease (0-7 days, sepsis/pneumonia) versus late-onset disease (7-90 days, meningitis), with risk factors and clinical presentations for each. Panel B: Streptococcus pneumoniae characteristics and diseases showing the lancet-shaped diplococci morphology, thick polysaccharide capsule with quellung reaction for serotyping, clinical diseases depicted (lobar pneumonia on chest X-ray, meningitis with CSF examination, otitis media with bulging tympanic membrane), and vaccine types (PCV13 conjugate and PPSV23 polysaccharide) with target populations. Panel C: Viridans streptococci and infective endocarditis pathway showing oral cavity colonization with mixed viridans species, dental procedure causing transient bacteremia, bacteria seeding a previously abnormal heart valve (rheumatic, bicuspid, or prosthetic), vegetation formation and growth, and clinical manifestations including embolic phenomena (splinter hemorrhages, Janeway lesions, Osler nodes, retinal hemorrhages) with insidious constitutional symptoms. Panel D: Streptococcus gallolyticus and colorectal cancer association illustrated showing bacteremia from GI source, laboratory identification distinguishing it from other streptococci, strong association with colorectal neoplasia (both adenomas and carcinomas), and recommended workup pathway with colonoscopy following any S. gallolyticus isolation from blood.</image>

VIII. Enterococcus

The enterococci were formerly classified as Group D streptococci but are now recognized as a distinct genus with significant clinical importance. These organisms are normal inhabitants of the gastrointestinal tract and possess intrinsic resistance to many antibiotics, making infections challenging to treat. The emergence and spread of vancomycin-resistant enterococci (VRE) has created a major public health concern, particularly in healthcare settings where these organisms cause difficult-to-treat infections in vulnerable patient populations.

Enterococci are gram-positive cocci that appear in pairs or short chains, resembling streptococci morphologically. Like streptococci, they are catalase-negative. They typically produce gamma-hemolysis (no hemolysis) or alpha-hemolysis on blood agar. Enterococci are distinguished by their ability to grow under adverse conditions: they tolerate bile salts (growing on bile esculin agar and hydrolyzing esculin to produce a black color), grow in 6.5% sodium chloride, and hydrolyze PYR (pyrrolidonyl-beta-naphthylamide). These properties enable laboratory identification and reflect the organisms' adaptation to the intestinal environment. The two most clinically important species are Enterococcus faecalis, which accounts for 80 to 90 percent of enterococcal infections and is generally more susceptible to antibiotics, and Enterococcus faecium, which is more commonly resistant to ampicillin and vancomycin.

Clinical infections caused by enterococci most commonly involve the urinary tract, bloodstream, and endocardium. Urinary tract infections are the most frequent enterococcal infections, often occurring in hospitalized patients with urinary catheters, structural abnormalities, or recent instrumentation. Bacteremia typically arises from urinary, biliary, or intraabdominal sources, or from intravascular catheter infections. Enterococcal endocarditis accounts for approximately 10 percent of infective endocarditis cases and tends to pursue an indolent course similar to viridans streptococcal endocarditis; it typically affects abnormal native valves or prosthetic valves. Enterococci frequently participate in polymicrobial intraabdominal and wound infections, though their pathogenic contribution in these mixed infections is debated, and not all authorities recommend specific anti-enterococcal coverage for polymicrobial infections unless the patient is severely ill or immunocompromised.

Enterococci possess intrinsic resistance to many antibiotics that are active against other gram-positive cocci. They are intrinsically resistant to cephalosporins, have low-level resistance to aminoglycosides (which can be overcome with synergistic beta-lactam therapy), and are relatively resistant to penicillin compared to streptococci. This intrinsic resistance limits treatment options even before considering acquired resistance. Vancomycin-resistant enterococci (VRE), particularly E. faecium, have become endemic in many healthcare facilities. Vancomycin resistance is mediated by genes, primarily vanA and vanB, that encode modified peptidoglycan precursors to which vancomycin cannot bind. VanA confers high-level resistance to both vancomycin and teicoplanin and is transferable on plasmids, raising concern about potential transfer to other organisms including S. aureus. VanB confers resistance to vancomycin but not teicoplanin. Treatment options for VRE are limited and include linezolid, daptomycin, and tigecycline. Infection control measures including contact precautions for colonized or infected patients are essential to prevent VRE spread within healthcare facilities.

<image>Panel A: Enterococcus characteristics and identification showing gram-positive cocci in pairs and short chains, gamma-hemolytic colonies on blood agar, and biochemical identification tests: bile esculin agar with black coloration (positive), growth in 6.5% NaCl broth (positive), and PYR test (positive), distinguishing enterococci from group D streptococci which are bile esculin positive but do not grow in 6.5% NaCl. Panel B: Enterococcal infection sources and types illustrated on a human body diagram: urinary tract infection arising from catheterized bladder, bacteremia originating from GI or biliary source, endocarditis on abnormal or prosthetic valve, and intraabdominal infection as component of polymicrobial flora, with arrows indicating typical portal of entry for each infection type and E. faecalis versus E. faecium prevalence noted. Panel C: Vancomycin resistance mechanism diagram showing normal peptidoglycan synthesis with D-Ala-D-Ala terminus to which vancomycin binds, and VRE with modified D-Ala-D-Lac terminus to which vancomycin cannot bind, along with genetic elements vanA (high-level, plasmid-mediated, vancomycin and teicoplanin resistant) and vanB (moderate-level, vancomycin resistant only), with concern about horizontal transfer illustrated. Panel D: Treatment algorithm for enterococcal infections showing decision tree: susceptibility testing determining path to ampicillin-sensitive (treat with ampicillin plus gentamicin for endocarditis), ampicillin-resistant but vancomycin-sensitive (treat with vancomycin), and VRE (treat with linezolid, daptomycin, or tigecycline), with infection control measures for VRE including contact precautions, hand hygiene, and environmental cleaning emphasized.</image>

IX. Laboratory Identification

Accurate laboratory identification of gram-positive cocci is essential for guiding appropriate antimicrobial therapy and predicting clinical behavior. The systematic approach to identification uses a combination of Gram stain morphology, hemolysis patterns, and biochemical tests that progressively narrow the differential diagnosis. Modern laboratories also employ molecular methods and mass spectrometry for rapid and definitive identification, but traditional methods remain important for understanding the basis of identification and for resource-limited settings.

The identification of staphylococci begins with the catalase test, which distinguishes catalase-positive staphylococci from catalase-negative streptococci and enterococci. The test is performed by adding hydrogen peroxide to bacteria on a glass slide; staphylococci produce vigorous bubbling as catalase converts hydrogen peroxide to water and oxygen, while streptococci show no reaction. Once staphylococcus is established, the coagulase test differentiates S. aureus from coagulase-negative staphylococci. The tube coagulase test mixes bacteria with rabbit plasma and incubates for up to 24 hours, with clot formation indicating a positive result; the slide coagulase test detects clumping factor (bound coagulase) more rapidly. Alternatively, latex agglutination tests detect protein A and clumping factor. For coagulase-negative staphylococci, novobiocin susceptibility testing distinguishes S. saprophyticus (resistant) from S. epidermidis and most other CoNS (susceptible). Species-level identification of CoNS can be achieved with commercial biochemical panels, MALDI-TOF mass spectrometry, or molecular methods when clinically necessary.

Streptococcal identification begins with observation of hemolysis pattern on blood agar. Beta-hemolytic streptococci are further characterized by Lancefield grouping, which detects cell wall carbohydrate antigens. Traditional serologic methods have been largely replaced by latex agglutination tests and direct detection methods. The PYR test (pyrrolidonyl arylamidase activity) is positive for S. pyogenes and enterococci but negative for other beta-hemolytic streptococci. Bacitracin susceptibility (S. pyogenes susceptible, other groups resistant) provides another differentiating feature. For alpha-hemolytic streptococci, the optochin susceptibility test differentiates S. pneumoniae (sensitive, showing a zone of inhibition around an optochin disk) from viridans streptococci (resistant). Bile solubility confirms pneumococcal identification: S. pneumoniae autolysins are activated by bile salts, causing the organism to lyse; viridans streptococci remain intact. For enterococci, growth in bile esculin agar with blackening (esculin hydrolysis) and growth in 6.5% NaCl broth distinguish them from group D streptococci like S. gallolyticus.

Antimicrobial susceptibility testing is critical for guiding therapy, given the varying resistance patterns among gram-positive cocci. Disk diffusion (Kirby-Bauer method) provides qualitative results categorizing organisms as susceptible, intermediate, or resistant. Minimum inhibitory concentration (MIC) determination by broth dilution or gradient diffusion (Etest) provides quantitative results important for serious infections. For staphylococci, detection of methicillin resistance (which implies resistance to all beta-lactams except ceftaroline and ceftobiprole) can be performed by cefoxitin disk diffusion, which correlates with mecA gene presence, or by direct mecA PCR. The mecA gene encodes PBP2a, a penicillin-binding protein with reduced affinity for beta-lactams that allows cell wall synthesis to continue in the presence of these drugs. For enterococci, vancomycin susceptibility must be determined, and high-level aminoglycoside resistance (indicating inability to achieve synergistic bactericidal therapy) should be evaluated for serious infections like endocarditis. Molecular methods including vanA and vanB PCR can rapidly detect vancomycin resistance genes.

<image>Panel A: Staphylococcus identification algorithm as a flowchart beginning with gram-positive cocci in clusters, proceeding to catalase test (positive confirms Staphylococcus), then coagulase test branching to S. aureus (positive) versus coagulase-negative staphylococci (negative), and finally novobiocin susceptibility for CoNS branching to S. saprophyticus (resistant) versus S. epidermidis and others (susceptible), with images of each key test result. Panel B: Streptococcus identification algorithm beginning with gram-positive cocci in chains, catalase negative confirming Streptococcus/Enterococcus, branching by hemolysis: beta-hemolytic pathway with Lancefield grouping to Group A (S. pyogenes, PYR+, bacitracin sensitive), Group B (S. agalactiae), or others; alpha-hemolytic pathway with optochin sensitivity to S. pneumoniae (sensitive, bile soluble) versus viridans streptococci (resistant). Panel C: Enterococcus identification showing gamma-hemolytic colonies, positive bile esculin test (black color), growth in 6.5% NaCl, and PYR positive result, with species differentiation showing E. faecalis (more common, often susceptible) versus E. faecium (more resistant, particularly to ampicillin and vancomycin). Panel D: Susceptibility testing methods illustrated: disk diffusion showing zones of inhibition around antibiotic disks with ruler measuring zone diameter, Etest showing gradient strip with MIC read at intersection with growth, broth microdilution plate with visible growth cutoff indicating MIC, and molecular methods showing PCR gel with mecA and vanA/vanB detection bands.</image>

X. Treatment Summary

The treatment of gram-positive coccal infections requires knowledge of the typical susceptibility patterns of each organism and the specific resistance mechanisms that may be present. While empiric therapy must often be initiated before susceptibility results are available, definitive therapy should be tailored to laboratory results. Treatment duration varies substantially depending on the site and severity of infection, and source control (such as drainage of abscesses or removal of infected devices) is often as important as antibiotic selection.

Treatment of Staphylococcus aureus infections depends critically on methicillin susceptibility. For methicillin-susceptible S. aureus (MSSA), beta-lactam antibiotics provide superior outcomes compared to alternative agents. Mild skin and soft tissue infections can be treated orally with dicloxacillin, cephalexin, or (for penicillin-allergic patients) clindamycin. Serious MSSA infections including bacteremia, endocarditis, and osteomyelitis require intravenous therapy with nafcillin, oxacillin, or cefazolin. For methicillin-resistant S. aureus (MRSA), treatment options are more limited. Mild skin and soft tissue infections may respond to trimethoprim-sulfamethoxazole or doxycycline orally. Serious MRSA infections require parenteral therapy with vancomycin, daptomycin, or linezolid. Vancomycin has been the traditional drug of choice but has limitations including nephrotoxicity and inferior outcomes compared to beta-lactams for MSSA. Daptomycin is inactivated by pulmonary surfactant and should not be used for pneumonia. Ceftaroline is a newer cephalosporin with activity against MRSA, approved for skin infections and pneumonia. For all S. aureus bacteremia, echocardiography to evaluate for endocarditis and investigation for metastatic foci of infection are recommended, and treatment duration depends on whether the infection is uncomplicated (two weeks) or complicated (four to six weeks or longer).

Streptococcal infections are generally highly susceptible to penicillin, which remains the treatment of choice for most streptococcal species. Streptococcus pyogenes has never developed penicillin resistance, making penicillin V or amoxicillin ideal for pharyngitis and penicillin G for serious infections. For invasive GAS infections including necrotizing fasciitis and toxic shock syndrome, clindamycin is added to penicillin because it inhibits toxin production and is not affected by the inoculum effect (reduced penicillin activity in large bacterial populations). Streptococcus agalactiae is also highly susceptible to penicillin and ampicillin. Streptococcus pneumoniae susceptibility to penicillin is variable and must be determined for serious infections; resistance is mediated by altered penicillin-binding proteins acquired through transformation. For pneumococcal pneumonia, standard doses of penicillin or amoxicillin remain effective against most strains, but meningitis requires higher doses of ceftriaxone or cefotaxime, often with vancomycin added empirically until susceptibilities are known. Viridans streptococci are usually susceptible to penicillin, and endocarditis is treated with penicillin plus gentamicin for synergistic bactericidal effect.

Enterococcal infections require specific anti-enterococcal therapy, as many antibiotics active against streptococci have no enterococcal activity. For susceptible strains, ampicillin is the drug of choice. Enterococci are intrinsically resistant to cephalosporins and have low-level aminoglycoside resistance, but high doses of aminoglycosides combined with cell wall-active agents (ampicillin or vancomycin) achieve synergistic bactericidal activity needed for endocarditis. High-level aminoglycoside resistance eliminates this synergism and necessitates prolonged therapy or alternative combinations. For ampicillin-resistant, vancomycin-susceptible strains, vancomycin is used. Vancomycin-resistant enterococci present the greatest therapeutic challenge, with options including linezolid (bacteriostatic, risk of thrombocytopenia and neuropathy with prolonged use), daptomycin (higher doses often used, not for respiratory tract infections), and tigecycline (low serum levels limit use for bacteremia). Duration of therapy varies from short courses for uncomplicated UTI to four to six weeks for endocarditis.

<image>Panel A: MSSA versus MRSA treatment algorithm showing the central question of methicillin susceptibility, branching to MSSA treatment (preferred: nafcillin, oxacillin, cefazolin for serious infections; dicloxacillin, cephalexin for mild) and MRSA treatment (preferred: vancomycin for serious; TMP-SMX or doxycycline for mild; alternatives: daptomycin, linezolid, ceftaroline), with notes on why beta-lactams are preferred for MSSA and limitations of each MRSA agent. Panel B: Streptococcal treatment guide displayed by species: S. pyogenes (penicillin always effective, add clindamycin for toxin-mediated disease), S. agalactiae (penicillin or ampicillin), S. pneumoniae (determine susceptibility; penicillin for respiratory, ceftriaxone/vancomycin for meningitis), viridans streptococci (penicillin plus aminoglycoside for endocarditis), with dosing considerations for serious infections. Panel C: Enterococcal treatment decision pathway showing sequential questions: ampicillin susceptible (treat with ampicillin plus gentamicin for endocarditis), ampicillin resistant but vancomycin susceptible (treat with vancomycin), VRE (treat with linezolid or daptomycin), with high-level aminoglycoside resistance as a modifier affecting synergistic therapy for endocarditis. Panel D: Treatment duration guidelines displayed as a visual timeline showing recommended durations for different infection types: uncomplicated skin infections (5-7 days), urinary tract infections (3-7 days depending on agent), uncomplicated bacteremia (2 weeks minimum), endocarditis (4-6 weeks), and osteomyelitis (4-6 weeks or longer), with factors that may extend duration listed.</image>

Summary

• Staphylococci are gram-positive cocci in clusters, catalase-positive; S. aureus is coagulase-positive, possesses numerous virulence factors (protein A, hemolysins, PVL, toxins), and causes skin infections, invasive disease, and toxin-mediated syndromes (TSS, SSSS, food poisoning)
• MRSA carries the mecA gene encoding PBP2a, conferring resistance to all beta-lactams except ceftaroline; treatment requires vancomycin, daptomycin, or linezolid for serious infections
• Coagulase-negative staphylococci include S. epidermidis (device infections via biofilm), S. saprophyticus (UTI in young women, novobiocin-resistant), and S. lugdunensis (aggressive infections despite CoNS status)
• Streptococci are gram-positive cocci in chains, catalase-negative, classified by hemolysis (alpha, beta, gamma) and Lancefield grouping for beta-hemolytic species
• S. pyogenes (GAS) causes pharyngitis, skin infections, invasive disease, and post-streptococcal complications (ARF, PSGN); treatment with penicillin prevents ARF; no penicillin resistance has developed
• S. agalactiae (GBS) causes neonatal sepsis and meningitis; prevention through universal screening and intrapartum prophylaxis
• S. pneumoniae is the most common cause of bacterial pneumonia and meningitis; capsular vaccines (PCV13, PPSV23) provide protection; penicillin resistance is emerging
• Enterococci cause UTI, bacteremia, and endocarditis; intrinsic resistance to many antibiotics; VRE (vanA, vanB genes) requires linezolid, daptomycin, or tigecycline
• Laboratory identification uses catalase (staph vs strep), coagulase (S. aureus vs CoNS), hemolysis pattern, Lancefield grouping, optochin sensitivity (pneumococcus), and bile esculin/NaCl tolerance (enterococci)

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown